Skip to content
Study details
Enrolling now

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

University of Virginia
NCT IDNCT04465500ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 8.4 years

Ages

18+

Sex

Male only

Locations

1 site in VA

What this study is about

Researchers are testing if a combination of androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments leads to less side effects. The trial also looks at patient outcomes, quality of life, and overall survival for patients receiving this treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive External Beam Radiation
  • 2.Receive HDR Brachytherapy
  • 3.Take Androgen Deprivation Therapy

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

hormone therapy

Endpoints

Primary: Compare GU toxicity rate to the rate published in the ASCENDE-RT trial

Secondary: Describe impact of treatment on quality of life, Estimate GI and sexual toxicity, Estimate freedom from biochemical failure (RFS), Estimate the prevalence of grade 3 or greater GU toxicity

Procedures

radiation

Body systems

Oncology